Stratégie Santé | Actualités
business
Les dernières nouvelles
Retour
Image non disponibleQuelques fusions / acquisitions
Date de publication: 19 May 2020

BOEHRINGER-INGELHEIM (Allemagne) / NORTHERN BIOLOGICS (Canada)

Acquisition de produits au stade pré clinique
Two preclinical programs developed by Canadian biotech Northern Biologics have been acquired by privately held German company Boehringer Ingelheim, which is looking to bolster its cancer immunology portfolio.
The assets acquired from Northern Biologics in the deal, announced Thursday, are designed to target two aspects of what’s known as the tumor microenvironment: stroma, or connective tissue made up of different cell types, and myeloid cells.
Financial terms weren’t disclosed, although the companies said the agreement includes an upfront payment as well as other potential payments tied to the drug candidates’ progress.

PTC THERAPEUTICS (USA) : Acquisition de CENSA (USA)

PTC Therapeutics, Inc. announced that it has entered into an agreement to acquire Censa Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of CNSA-001 (sepiapterin), a clinical-stage investigational therapy for orphan metabolic diseases, including phenylketonuria (PKU) and other diseases associated with defects in the tetrahydrobiopterin (BH4) biochemical pathways diagnosed at birth. The transaction was approved by the Boards of both companies.

ASTELLAS  (Japon) acquisition de NANNA THERAPEUTICS  (UK)


Astellas Pharma Inc and Nanna Therapeutics Limited announced that Astellas has acquired Nanna, a biotech company headquartered in the United Kingdom, that is focused on addressing age-related diseases with high unmet medical need including mitochondria-related diseases. Astellas, through its subsidiary in the United Kingdom, Astellas Pharma Europe Ltd., has purchased all of the issued share capital of Nanna through execution of a Share Purchase Agreement. Consideration for the acquisition, £12 million, was paid upon closing of the acquisition, and Nanna became a wholly owned subsidiary of Astellas. In addition to this payment, Nanna’s shareholders are eligible to receive potential future development milestone payments of up to £57.5 million.

NOVARTIS (Suisse) acquiert AMBLYOTECH (USA)

NOVARTIS a annoncé l'acquisition de la start-up américaine Amblyotech pour un montant non communiqué. Le groupe pharmaceutique suisse s'associera à Ubisoft et à l'université McGill pour poursuivre le développement d'un traitement du trouble visuel appelé amblyopie, ou "oeil paresseux ». Amblyotech utilise une technologie de jeu actif et de vidéo passive avec des lunettes 3D pour entraîner les yeux à travailler ensemble pour voir une image dans son intégralité, a indiqué Novartis.

Le groupe suisse prévoit de travailler en partenariat avec le développeur de jeux vidéo Ubisoft afin de développer le logiciel d'Amblyotech en tant que dispositif médical, créer une série de jeux attrayants pour le dispositif et mener une étude de preuve de concept, prévue dans le courant de l'année 2020, a-t-il indiqué.

Sources : Agences de Presse et communiqués d’entreprises

STRATÉGIE SANTÉ
19, rue Georges Clemenceau
78000 Versailles - France
Tél. +33 (0)1 42 86 86 00
contact@strategiesante.com